PRORADNOR-RCT Proton Versus Photon Therapy in Head and Neck Squamous Cell Carcinomas. A Randomised, Multicentre, Phase III Clinical Trial.
Trial Snapshot
- Phase
- Phase 3
- Status
- Recruiting
- Sponsor
- Enrollment
- 400
- Locations
- 4
Study Overview
Brief Summary
A national, randomized, clinical trial (phase III) investigating radiotherapy with protons compared with photons for patients with squamous cell carcinoma of the head and neck area eligible for radiotherapy, either radical or postoperative, with curative intent. Comparative dose plans with protons and photons will be prepared, and the probability of toxicity evaluated with NTCP models. Patients with presumed benefit from protons will be randomized 1:1 to treatment with protons or photons. The number of randomized participants will be 400. The primary endpoint is "combined toxicity burden" - dry mouth, difficulty swallowing, pain and affected speech in the period after the end of radiotherapy to 12 months after treatment.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 40 Years to 90 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Signed informed consent.
- •Age ≥ 40 years.
- •Histological or cytological verified squamous cell carcinoma of the following head and neck regions; oral cavity, oropharynx, hypopharynx or larynx.
- •Planned for standard radiotherapy with curative intent, either as definitive or postoperative treatment with or without concomitant chemotherapy (cisplatin).
- •ECOG performance status 0-
- •Ability to fill in patient questionnaires and comply with study procedures.
- •Able to answer questionnaires in Norwegian or English.
- •Willing to travel to Oslo or Bergen for proton therapy if randomised to experimental arm.
Exclusion Criteria
- •Glottic cancers, cT1-T2 cN0 cM
- •Nasopharyngeal carcinomas, sino-nasal cancers, and head and neck salivary gland carcinomas.
- •Distant metastasis.
- •Previous radiotherapy to the head and neck.
- •Patients with pacemakers and/or implanted defibrillators.
- •Prior malignancy within the last 5 years. Not including radically resected non-melanoma skin cancer or low-risk early-stage prostate cancer.
- •Not able to participate due to equipment restrictions (weight limit treatment board 150 kg).
- •Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could, at the investigator's opinion, interfere with the participant's safety or study participation.
Investigators
Hanne Astrid Eide
Principal Investigator
Oslo University Hospital